ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer

10 Nov 2022 09:00:02 By Nasdaq GlobeNewswire

Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences

09 Nov 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology

03 Nov 2022 09:04:36 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase

02 Nov 2022 16:02:00 By Nasdaq GlobeNewswire

Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia

31 Oct 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022

26 Oct 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products

11 Oct 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial

06 Oct 2022 16:15:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit

23 Sep 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Second Quarter 2022 Financial Results

09 Aug 2022 16:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

03 Aug 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

27 Jul 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors

12 Jul 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma

08 Jun 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

19 May 2022 08:30:01 By Nasdaq GlobeNewswire

Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal

09 May 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports First Quarter 2022 Financial Results

04 May 2022 16:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer

28 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022

27 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma

27 Apr 2022 08:00:01 By Nasdaq GlobeNewswire